Virtual Poster Session: Practical Application of Key Data Presented During the 2016 Gastrointestinal Cancers Symposium - priME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session: Practical Application of Key Data Presented During the 2016 Gastrointestinal Cancers Symposium

Not a member of My prIME? Join now for instant access.

Virtual Poster Session: Practical Application of Key Data Presented During the 2016 Gastrointestinal Cancers Symposium

View Activity

Activity Overview

View CME-certified abstract presentations and downloadable slides from the 2016 Gastrointestinal Cancers Symposium in San Francisco.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Gastrointestinal Cancer

György Bodoky, MD, PhD

Abstract #45: Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma

Presented by: György Bodoky, MD, PhD

Sonia Yip, PhD

Abstract #64: Evaluation of circulating VEGF based biomarkers in INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG)

Presented by: Sonia Yip, PhD

George Demetri, MD

Abstract #156: Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal tumors (GIST)

Presented by: George Demetri, MD

Metastatic Colorectal Cancer

Johanna Bendell, MD

Abstract #492: Overall response rate (ORR) in STEAM, a randomized open-label, phase 2 trial of sequential concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC)

Presented by: Johanna Bendell, MD

Marc Peeters, MD, PhD

Abstract #519: Efficacy of panitumumab (pmab) vs cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT

Presented by: Marc Peeters, MD, PhD

Eric Van Cutsem, MD, PhD

Abstract #647: Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study

Presented by: Eric Van Cutsem, MD, PhD

Yoshito Komatsu, MD, PhD

Abstract #680: Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim results from postmarketing surveillance (PMS)

Presented by: Yoshito Komatsu, MD, PhD

Udit Verma, MD, DM

Abstract #735: Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study

Presented by: Udit Verma, MD, DM

Johanna Bendell, MD

Abstract #TPS789: KEYNOTE-177: First-line, open-label, randomized, phase 3 study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma

Presented by: Johanna Bendell, MD

Support

This educational activity is supported by grants from Merck & Co., Inc.; and Bayer HealthCare Pharmaceuticals, Inc.